← Back to Search

Cardiac Resynchronization Therapy

aCRT ON for Heart Failure

N/A

Waitlist Available

Research Sponsored by Medtronic Cardiac Rhythm and Heart Failure

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from subject randomization until study exit, median follow-up 4.9 years (max. follow-up 8.1 years)

Awards & highlights

Study Summary

This trial will test if a new type of CRT device is more effective than the standard CRT device for patients with normal AV conduction and LBBB.

Eligible Conditions

Heart Failure With Left Bundle Branch Block

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from subject randomization until study exit, median follow-up 4.9 years (max. follow-up 8.1 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from subject randomization until study exit, median follow-up 4.9 years (max. follow-up 8.1 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from subject randomization until study exit, median follow-up 4.9 years (max. follow-up 8.1 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation

Secondary outcome measures

All-cause Mortality

All-cause Re-admissions Within 30 Days After a Heart Failure Admission Per 100 Patient Years

Atrial Fibrillation

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: aCRT ONExperimental Treatment1 Intervention

The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise

Group II: aCRT OFFActive Control1 Intervention

Standard CRT

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

aCRT ON

2014

N/A

~3980

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Medtronic Cardiac Rhythm and Heart FailureLead Sponsor

198 Previous Clinical Trials

125,133 Total Patients Enrolled

79 Trials studying Heart Failure

65,833 Patients Enrolled for Heart Failure

Kweli Thompson, MDStudy DirectorMedtronic Cardiac Rhythm Heart Failure

Bruce Wilkoff, MDStudy ChairThe Cleveland Clinic

3 Previous Clinical Trials

8,976 Total Patients Enrolled

1 Trials studying Heart Failure

1,701 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently any availability for this research initiative?

"According to the official listing on clinicaltrials.gov, this medical trial has ceased recruitment of participants and is no longer actively searching for candidates. It was initially posted in July 2014 with its last update occurring on June 14th 2022; however, there are still 20 other studies that require patients at present."

Answered by AI

How widely dispersed is the testing of this experiment in North America?

"Currently, 99 locations worldwide are running this trial. The main sites are in Cincinnati, Newmarket and Eugene but there is a wide selection of other available options for participants to choose from. To reduce the burden of travel it's wise to pick the closest site to you if taking part in the study."

Answered by AI

Recent research and studies

ESC Heart FailureJournal

Differences in Clinical Characteristics and Reported Quality of Life of Men and Women Undergoing Cardiac Resynchronization Therapy

Wilkoff, Bruce L., David Birnie, Michael R. Gold, Ahmad S. Hersi, Sandra Jacobs, Bart Gerritse, Kengo Kusano, Christophe Leclercq, Wilfried Mullens, and Gerasimos Filippatos. 2020. “Differences in Clinical Characteristics and Reported Quality of Life of Men and Women Undergoing Cardiac Resynchronization Therapy”. ESC Heart Failure. Wiley. doi:10.1002/ehf2.12914.

European Journal of Heart FailureJournal

Rationale and Design of the Adaptresponse Trial: A Prospective Randomized Study of Cardiac Resynchronization Therapy with Preferential Adaptive Left Ventricular-only Pacing

Filippatos, Gerasimos, David Birnie, Michael R. Gold, Bart Gerritse, Ahmad Hersi, Sandra Jacobs, Kengo Kusano, et al.. 2017. “Rationale and Design of the Adaptresponse Trial: A Prospective Randomized Study of Cardiac Resynchronization Therapy with Preferential Adaptive Left Ventricular-only Pacing”. European Journal of Heart Failure. Wiley. doi:10.1002/ejhf.895.

clinicaltrials.govStudy

AdaptResponse Clinical Trial

2014. "AdaptResponse Clinical Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02205359.